Printed from Voxsanity (voxsanity.com.au) — NCT07271602 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07271602
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 75 years.
- People whose lung cancer has been confirmed by laboratory tissue or cell testing as either squamous cell carcinoma or adenocarcinoma of the lung.
- People whose cancer is at stage IV, meaning it has spread to distant parts of the body, and who have at least 2 measurable tumour areas, including one that has spread to a distant location.
- People whose cancer does not have specific gene changes (known as "driver gene-negative") (confirm with trial site).
- People who are generally able to carry out daily activities with little to no limitation, based on a standard medical scale called ECOG, scored 0 or 1.
- People whose blood cell counts are within acceptable ranges: white blood cells above a certain level, haemoglobin above 90 g/L, and platelets above a certain level.
- People whose liver and kidney function test results are within acceptable ranges, including bilirubin, liver enzymes (AST, ALT, ALP), and kidney filtration rate.
- People with normal results for thyroid, pancreas, pituitary, heart enzyme, and heart tracing (ECG) tests — with additional heart and lung tests required for certain people based on age, smoking history, or heart conditions that do not meet the exclusion rules (confirm with trial site).
- People who have signed a consent form and are willing and able to attend follow-up appointments, receive treatment, and complete required tests as set out in the study schedule.
- Women who could become pregnant must agree to use reliable contraception from the screening stage until one year after treatment ends.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who test positive for hepatitis B surface antigen with a high level of hepatitis B virus detected in the blood, or who test positive for hepatitis C antibodies.
- People who test positive for HIV antibodies or who have been diagnosed with AIDS.
- People with active tuberculosis (TB) within the past year, or people with a history of TB from more than one year ago who did not receive confirmed, regular anti-TB treatment.
- People with active, known, or suspected autoimmune diseases — such as certain conditions affecting the eyes, gut, liver, kidneys, blood vessels, thyroid, or lungs — though some exceptions apply, including type 1 diabetes, hypothyroidism treated with hormone replacement, and certain skin conditions not requiring systemic treatment (confirm with trial site).
- People who have had an interstitial lung disease or lung inflammation in the past year that required steroid tablets or intravenous steroids.
- People currently taking ongoing steroid tablets or other medicines that suppress the immune system at certain doses — though people using inhaled or skin-applied steroids may still be eligible (confirm with trial site).
- People with certain uncontrolled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, or certain heart rhythm problems requiring treatment.
- Women who are pregnant or breastfeeding.
- People who have had, or currently have, another type of cancer — with some exceptions for certain skin cancers, early-stage cervical changes, and a specific type of thyroid cancer that has been adequately treated.
- People with a known allergy or sensitivity to the study drug (QL1706) or similar protein-based medicines.
- People who have had an active infection requiring systemic treatment within the past week.
- People who have received a live vaccine within 30 days before starting the immunotherapy part of the trial.
- People who have had an organ transplant.
- People whom the trial investigators consider unsuitable due to other safety concerns, serious health conditions requiring urgent treatment, significantly abnormal test results, or other personal or social risk factors.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 027 83262731
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
30 January 2026
Est. completion
31 December 2026
Primary endpoints
Objective Response Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.